-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today Aptose Bioscience announced that its multi-kinase inhibitor Luxeptinib (formerly known as CG-806) produced a complete response in the early clinical stage of an acute myeloid leukemia (AML).
Drug source analysis
Drug source analysisLuxe was originally developed as a reversible BTK inhibitor and its main use is chronic leukemia, but so far it is still a substitute goalkeeper in this arena.
One potential problem with covalent compounds is the so-called off-target side effects.
But even patients with off-target side effects of serious diseases such as tumors sometimes can't bear it, and Luxe came into being.
Off-target activity is one of the main differences between small molecule drugs and biological drugs.